Modification of quasi-morphine withdrawal with serotonin agonists and antagonists: evidence for a role of serotonin in the expression of opiate withdrawal

Psychopharmacology (Berl). 1989;98(2):231-5. doi: 10.1007/BF00444696.

Abstract

Methylxanthines produce a quasi-morphine withdrawal syndrome (QMWS) in opiate naive rats. Additionally, methylxanthine-induced suppression of conditioned behavior in rats is reversed by the alpha 2 adrenergic agonist clonidine which also attenuates true opiate withdrawal and the QMWS. Therefore, the operant behavioral effects of 3-isobutyl-1-methylxanthine (IBMX) provide a model with which to study mechanisms involved in the expression of opiate withdrawal. In order to examine the role of serotonin (5-HT) in the rate-decreasing effects of IBMX on operant behavior, the 5-HT precursor 5-hydroxytryptophan, and 5-HT reuptake blocker fluoxetine were administered in combination with IBMX to rats performing a fixed-ratio 30 operant for food reinforcement. Both drugs failed to reverse the behavioral suppression caused by relatively low doses of IBMX, suggesting that elevated 5-HT neurotransmission contributes to, rather than attenuates, the QMWS. The relatively selective 5-HT2 antagonists mianserin and pirenperone blocked the IBMX-induced suppression, whereas the classic 5-HT antagonist methysergide had no effect. The results indicate that the operant behavioral effects of IBMX and possibly the QMWS may be mediated by serotonergic mechanisms.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • 5-Hydroxytryptophan / pharmacology
  • Animals
  • Fluoxetine / pharmacology
  • Male
  • Methysergide / pharmacology
  • Mianserin / pharmacology
  • Morphine / pharmacology*
  • Piperidines / pharmacology
  • Rats
  • Serotonin / physiology*
  • Serotonin Antagonists / pharmacology*
  • Substance Withdrawal Syndrome / prevention & control*
  • Substance Withdrawal Syndrome / psychology

Substances

  • Piperidines
  • Serotonin Antagonists
  • Fluoxetine
  • Mianserin
  • Serotonin
  • Morphine
  • 5-Hydroxytryptophan
  • 1-Methyl-3-isobutylxanthine
  • Methysergide
  • pirenperone